

JPMORGAN CHASE & CO

Form 424B2

December 06, 2018

The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

Subject to completion dated December 6, 2018

Registration Statement Nos. 333-222672 and 333-222672-01; Rule 424(b)(2)

December , 2018

JPMorgan Chase Financial Company LLC

Structured Investments

Review Notes Linked to the Lesser Performing of the S&P 500<sup>®</sup> Index and the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF due December 21, 2023

Fully and Unconditionally Guaranteed by JPMorgan Chase & Co.

The notes are designed for investors who seek early exit prior to maturity at a premium if, on any Review Date, the closing value of each of the S&P 500<sup>®</sup> Index and the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, which we refer to as the Underlyings, is at or above its Call Value.

The earliest date on which an automatic call may be initiated is December 27, 2019.

The notes are also designed for investors who seek a fixed return at maturity equal to the Contingent Minimum Return of 10.00% if the notes have not been automatically called and the Final Value of each Underlying is greater than or equal to 60.00% of its Initial Value.

Investors in the notes should be willing to forgo interest and dividend payments and be willing to accept the risk of losing some or all of their principal amount at maturity.

The notes are unsecured and unsubordinated obligations of JPMorgan Chase Financial Company LLC, which we refer to as JPMorgan Financial, the payment on which is fully and unconditionally guaranteed by JPMorgan Chase & Co.

**Any payment on the notes is subject to the credit risk of JPMorgan Financial, as issuer of the notes, and the credit risk of JPMorgan Chase & Co., as guarantor of the notes.**

Payments on the notes are not linked to a basket composed of the Underlyings. Payments on the notes are linked to the performance of each of the Underlyings individually, as described below.

Minimum denominations of \$1,000 and integral multiples thereof

The notes are expected to price on or about December 18, 2018 and are expected to settle on or about December 26, 2018.

CUSIP: 48130WKA8

**Investing in the notes involves a number of risks. See “Risk Factors” beginning on page PS-10 of the accompanying product supplement, “Risk Factors” beginning on page US-1 of the accompanying underlying supplement and “Selected Risk Considerations” beginning on page PS-5 of this pricing supplement.**

Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of the notes or passed upon the accuracy or the adequacy of this pricing supplement or the accompanying product supplement, underlying supplement, prospectus supplement and prospectus. Any representation to the contrary is a criminal offense.

Price to Public (1) Fees and Commissions (2)(3) Proceeds to Issuer

Per note \$1,000	\$	\$
Total	\$	\$

(1) See “Supplemental Use of Proceeds” in this pricing supplement for information about the components of the price to public of the notes.

(2) J.P. Morgan Securities LLC, which we refer to as JPMS, acting as agent for JPMorgan Financial, will pay all of the selling commissions it receives from us to other affiliated or unaffiliated dealers. In no event will these selling commissions exceed \$22.50 per \$1,000 principal amount note. See “Plan of Distribution (Conflicts of Interest)” in the accompanying product supplement.

(3) JPMS will pay a referral fee of \$4.50 per \$1,000 principal amount note to an affiliated or unaffiliated dealer and may pay a structuring fee of \$5.00 per \$1,000 principal amount note with respect to some or all of the notes to other affiliated or unaffiliated dealers.

**If the notes priced today, the estimated value of the notes would be approximately \$957.00 per \$1,000 principal amount note. The estimated value of the notes, when the terms of the notes are set, will be provided in the pricing supplement and will not be less than \$920.00 per \$1,000 principal amount note. See “The Estimated Value of the Notes” in this pricing supplement for additional information.**

*The notes are not bank deposits, are not insured by the Federal Deposit Insurance Corporation or any other governmental agency and are not obligations of, or guaranteed by, a bank.*

Pricing supplement to product supplement no. 4-I dated April 5, 2018, underlying supplement no. 1-I dated April 5, 2018 and the prospectus and prospectus supplement, each dated April 5, 2018

## Key Terms

**Issuer:** JPMorgan Chase Financial Company LLC, an indirect, wholly owned finance subsidiary of JPMorgan Chase & Co.

**Guarantor:** JPMorgan Chase & Co.

**Underlyings:** The S&P 500<sup>®</sup> Index (Bloomberg ticker: SPX) (the “Index”) and the SPDR<sup>®</sup>S&P<sup>®</sup> Biotech ETF (Bloomberg ticker: XBI) (the “Fund”) (each of the Index and the Fund, an “Underlying” and collectively, the “Underlyings”)

**Call Premium Amount:** The Call Premium Amount with respect to each Review Date is set forth below:

first Review Date:	at least 11.15% x \$1,000
second Review Date:	at least 22.30% x \$1,000
third Review Date:	at least 33.45% x \$1,000
fourth Review Date:	at least 44.60% x \$1,000
final Review Date:	at least 55.75% x \$1,000

(in each case, to be provided in the pricing supplement)

**Call Value:** With respect to each Underlying, 100.00% of its Initial Value

**Contingent Minimum Return:** 10.00%

**Trigger Value:** With respect to each Underlying, 60.00% of its Initial Value

**Pricing Date:** On or about December 18, 2018

**Original Issue Date (Settlement Date):** On or about December 26, 2018

**Review Dates\*:** December 27, 2019, December 18, 2020, December 20, 2021, December 19, 2022 and December 18, 2023 (final Review Date)

**Call Settlement Dates\*:** January 2, 2020, December 23, 2020, December 23, 2021, December 22, 2022 and the Maturity Date

**Maturity Date\*:** December 21, 2023

\* Subject to postponement in the event of a market disruption event and as described under “General Terms of Notes — Postponement of a Determination Date — Notes Linked to Multiple Underlyings” and “General Terms of Notes — Postponement of a Payment Date” in the accompanying product supplement

### Automatic Call:

If the closing value of each Underlying on any Review Date is greater than or equal to its Call Value, the notes will be automatically called for a cash payment, for each \$1,000 principal amount note, equal to (a) \$1,000 *plus* (b) the Call Premium Amount applicable to that Review Date, payable on the applicable Call Settlement Date. No further

payments will be made on the notes.

**Payment at Maturity:**

If the notes have not been automatically called and the Final Value of each Underlying is greater than or equal to its Trigger Value, your payment at maturity per \$1,000 principal amount note will be calculated as follows:

$$\$1,000 + (\$1,000 \times \text{Contingent Minimum Return})$$

If the notes have not been automatically called and the Final Value of either Underlying is less than its Trigger Value, your payment at maturity per \$1,000 principal amount note will be calculated as follows:

$$\$1,000 + (\$1,000 \times \text{Lesser Performing Underlying Return})$$

*If the notes have not been automatically called and the Final Value of either Underlying is less than its Trigger Value, you will lose more than 40.00% of your principal amount at maturity and could lose all of your principal amount at maturity.*

**Lesser Performing Underlying:** The Underlying with the Lesser Performing Underlying Return

**Lesser Performing Underlying Return:** The lower of the Underlying Returns of the Underlyings

**Underlying Return:** With respect to each Underlying,

$$\frac{(\text{Final Value} - \text{Initial Value})}{\text{Initial Value}}$$

**Initial Value:** With respect to each Underlying, the closing value of that Underlying on the Pricing Date

**Final Value:** With respect to each Underlying, the closing value of that Underlying on the final Review Date

**Share Adjustment Factor:** The Share Adjustment Factor is referenced in determining the closing value of the Fund and is set equal to 1.0 on the Pricing Date. The Share Adjustment Factor is subject to adjustment upon the occurrence of certain events affecting the Fund. See “The Underlyings — Funds — Anti-Dilution Adjustments” in the accompanying product supplement for further information.

PS-1 | Structured Investments

Review Notes Linked to the Lesser Performing of the S&P 500<sup>®</sup> Index and the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF

How the Notes Work

**Payment upon an Automatic Call**

**Payment at Maturity If the Notes Have Not Been Automatically Called**

**Call Premium Amount**

The table below illustrates the hypothetical Call Premium Amount per \$1,000 principal amount note for each Review Date based on the minimum Call Premium Amounts set forth under “Key Terms — Call Premium Amount” above. The actual Call Premium Amounts will be provided in the pricing supplement and will not be less than the minimum Call Premium Amounts set forth under “Key Terms — Call Premium Amount.”

**Review Date Call Premium Amount**

First	\$111.50
Second	\$223.00
Third	\$334.50
Fourth	\$446.00
Final	\$557.50

PS-2 | Structured Investments

Review Notes Linked to the Lesser Performing of the S&P 500<sup>®</sup> Index and the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF

## Hypothetical Payout Examples

The following examples illustrate payments on the notes linked to two hypothetical Underlyings, assuming a range of performances for the hypothetical Lesser Performing Underlying on the Review Dates. **Each hypothetical payment set forth below assumes that the closing value of the Underlying that is not the Lesser Performing Underlying on each Review Date is greater than or equal to its Call Value (and therefore its Trigger Value).**

In addition, the hypothetical payments set forth below assume the following:

an Initial Value for the Lesser Performing Underlying of 100.00;  
a Call Value for the Lesser Performing Underlying of 100.00 (equal to 100.00% of its hypothetical Initial Value);  
a Trigger Value for the Lesser Performing Underlying of 60.00 (equal to 60.00% of its hypothetical Initial Value);  
the Call Premium Amounts are equal to the minimum Call Premium Amounts set forth under “Key Terms — Call Premium Amount” above; and

a Contingent Minimum Return of 10.00%.

The hypothetical Initial Value of the Lesser Performing Underlying of 100.00 has been chosen for illustrative purposes only and may not represent a likely actual Initial Value of either Underlying. The actual Initial Value of each Underlying will be the closing value of that Underlying on the Pricing Date and will be provided in the pricing supplement. For historical data regarding the actual closing values of each Underlying, please see the historical information set forth under “The Underlyings” in this pricing supplement.

Each hypothetical payment set forth below is for illustrative purposes only and may not be the actual payment applicable to a purchaser of the notes. The numbers appearing in the following examples have been rounded for ease of analysis.

### Example 1 — Notes are automatically called on the first Review Date.

Date	Closing Value of Lesser Performing Underlying	
First Review Date	110.00	Notes are automatically called
	Total Payment	\$1,111.50 (11.15% return)

Because the closing value of each Underlying on the first Review Date is greater than or equal to its Call Value, the notes will be automatically called for a cash payment, for each \$1,000 principal amount note, of \$1,111.50 (or \$1,000 *plus* the Call Premium Amount applicable to the first Review Date), payable on the applicable Call Settlement Date. No further payments will be made on the notes.

### Example 2 — Notes are automatically called on the final Review Date.

Date	Closing Value of Lesser Performing Underlying	
First Review Date	90.00	Notes NOT automatically called
Second Review Date	85.00	Notes NOT automatically called
Third Review Date	95.00	Notes NOT automatically called
Fourth Review Date	80.00	Notes NOT automatically called
Final Review Date	150.00	Notes are automatically called
	Total Payment	\$1,557.50 (55.75% return)

Because the closing value of each Underlying on the final Review Date is greater than or equal to its Call Value, the notes will be automatically called for a cash payment, for each \$1,000 principal amount note, of \$1,557.50 (or \$1,000 *plus* the Call Premium Amount applicable to the final Review Date), payable on the applicable Call Settlement Date.

which is the Maturity Date.

PS-3 | Structured Investments

Review Notes Linked to the Lesser Performing of the S&P 500<sup>®</sup> Index and the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF

**Example 3 — Notes have NOT been automatically called and the Final Value of the Lesser Performing Underlying is greater than or equal to its Trigger Value.**

Date	Closing Value of Lesser Performing Underlying	
First Review Date	90.00	Notes NOT automatically called
Second Review Date	85.00	Notes NOT automatically called
Third Review Date	95.00	Notes NOT automatically called
Fourth Review Date	90.00	Notes NOT automatically called
Final Review Date	60.00	Notes NOT automatically called; Final Value of Lesser Performing Underlying is greater than or equal to Trigger Value
	Total Payment	\$1,100.00 (10.00% return)

Because the notes have not been automatically called and the Final Value of the Lesser Performing Underlying is greater than or equal to its Trigger Value, the payment at maturity, for each \$1,000 principal amount note, will be \$1,100.00, calculated as follows:

$$\$1,000 + (\$1,000 \times 10.00\%) = \$1,100.00$$

**Example 4 — Notes have NOT been automatically called and the Final Value of the Lesser Performing Underlying is less than its Trigger Value.**

Date	Closing Value of Lesser Performing Underlying	
First Review Date	80.00	Notes NOT automatically called
Second Review Date	75.00	Notes NOT automatically called
Third Review Date	60.00	Notes NOT automatically called
Fourth Review Date	55.00	Notes NOT automatically called
Final Review Date	50.00	Notes NOT automatically called; Final Value of Lesser Performing Underlying is less than Trigger Value
	Total Payment	\$500.00 (-50.00% return)

Because the notes have not been automatically called, the Final Value of the Lesser Performing Underlying is less than its Trigger Value and the Lesser Performing Underlying Return is -50.00%, the payment at maturity will be \$500.00 per \$1,000 principal amount note, calculated as follows:

$$\$1,000 + [\$1,000 \times (-50.00\%)] = \$500.00$$

The hypothetical returns and hypothetical payments on the notes shown above apply **only if you hold the notes for their entire term or until automatically called**. These hypotheticals do not reflect the fees or expenses that would be associated with any sale in the secondary market. If these fees and expenses were included, the hypothetical returns and hypothetical payments shown above would likely be lower.

PS-4 | Structured Investments

Review Notes Linked to the Lesser Performing of the S&P 500<sup>®</sup> Index and the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF



## Selected Risk Considerations

An investment in the notes involves significant risks. These risks are explained in more detail in the “Risk Factors” sections of the accompanying product supplement and underlying supplement.

### **YOUR INVESTMENT IN THE NOTES MAY RESULT IN A LOSS —**

The notes do not guarantee any return of principal. If the notes have not been automatically called and the Final Value of either Underlying is less than its Trigger Value, you will lose 1% of the principal amount of your notes for every 1% that the Final Value of the Lesser Performing Underlying is less than its Initial Value. Accordingly, under these circumstances, you will lose more than 40.00% of your principal amount at maturity and could lose all of your principal amount at maturity.

### **CREDIT RISKS OF JPMORGAN FINANCIAL AND JPMORGAN CHASE & CO. —**

Investors are dependent on our and JPMorgan Chase & Co.’s ability to pay all amounts due on the notes. Any actual or potential change in our or JPMorgan Chase & Co.’s creditworthiness or credit spreads, as determined by the market for taking that credit risk, is likely to adversely affect the value of the notes. If we and JPMorgan Chase & Co. were to default on our payment obligations, you may not receive any amounts owed to you under the notes and you could lose your entire investment.

### **AS A FINANCE SUBSIDIARY, JPMORGAN FINANCIAL HAS NO INDEPENDENT OPERATIONS AND HAS LIMITED ASSETS —**

As a finance subsidiary of JPMorgan Chase & Co., we have no independent operations beyond the issuance and administration of our securities. Aside from the initial capital contribution from JPMorgan Chase & Co., substantially all of our assets relate to obligations of our affiliates to make payments under loans made by us or other intercompany agreements. As a result, we are dependent upon payments from our affiliates to meet our obligations under the notes. If these affiliates do not make payments to us and we fail to make payments on the notes, you may have to seek payment under the related guarantee by JPMorgan Chase & Co., and that guarantee will rank *pari passu* with all other unsecured and unsubordinated obligations of JPMorgan Chase & Co.

### **THE APPRECIATION POTENTIAL OF THE NOTES IS LIMITED TO ANY CALL PREMIUM AMOUNT PAID ON THE NOTES IF THE NOTES ARE AUTOMATICALLY CALLED,**

regardless of any appreciation of either Underlying, which may be significant. You will not participate in any appreciation of either Underlying.

### **YOUR ABILITY TO RECEIVE THE CONTINGENT MINIMUM RETURN MAY TERMINATE ON THE FINAL REVIEW DATE IF THE NOTES HAVE NOT BEEN AUTOMATICALLY CALLED —**

If the notes have not been automatically called and the Final Value of either Underlying is less than its Trigger Value, you will not be entitled to receive the Contingent Minimum Return at maturity. Under these circumstances, you will lose some or all of your principal amount at maturity.

### **POTENTIAL CONFLICTS —**

We and our affiliates play a variety of roles in connection with the notes. In performing these duties, our and JPMorgan Chase & Co.’s economic interests are potentially adverse to your interests as an investor in the notes. It is possible that hedging or trading activities of ours or our affiliates in connection with the notes could result in substantial returns for us or our affiliates while the value of the notes declines. Please refer to “Risk Factors — Risks Relating to Conflicts of Interest” in the accompanying product supplement.

### **JPMORGAN CHASE & CO. IS CURRENTLY ONE OF THE COMPANIES THAT MAKE UP THE S&P 500® INDEX,**

but JPMorgan Chase & Co. will not have any obligation to consider your interests in taking any corporate action that might affect the level of the Index.

### **RISKS ASSOCIATED WITH THE BIOTECHNOLOGY INDUSTRY WITH RESPECT TO THE SPDR® S&P® BIOTECH ETF —**

All or substantially all of the equity securities held by the SPDR® S&P® Biotech ETF are issued by companies whose primary line of business is directly associated with the biotechnology industry. As a result, the value of the notes may be subject to greater volatility and be more adversely affected by a single economic, political or regulatory occurrence affecting this industry than a different investment linked to securities of a more broadly diversified group of issuers. Biotechnology companies invest heavily in research and development, which may not necessarily lead to commercially successful products. These companies are also subject to increased governmental regulation, which may delay or inhibit the release of new products. Many biotechnology companies are dependent upon their ability to use and enforce intellectual property rights and patents. Any impairment of these rights may have adverse financial consequences. Biotechnology stocks, especially those of smaller, less-seasoned companies, tend to be more volatile than the overall market. Biotechnology companies can be significantly affected by technological change and obsolescence, product liability lawsuits and consequential high insurance costs. These factors could affect the biotechnology industry and could affect the value of the equity securities held by the SPDR® S&P® Biotech ETF and the price of the SPDR® S&P® Biotech ETF during the term of the notes, which may adversely affect the value of your notes.

**YOU ARE EXPOSED TO THE RISK OF DECLINE IN THE VALUE OF EACH UNDERLYING —**

Payments on the notes are not linked to a basket composed of the Underlyings and are contingent upon the performance of each individual Underlying. Poor performance by either of the Underlyings over the term of the notes may result in the notes not being automatically called on a Review Date, may negatively affect your payment at maturity and will not be offset or mitigated by positive performance by the other Underlying.

**YOUR PAYMENT AT MATURITY WILL BE DETERMINED BY THE LESSER PERFORMING UNDERLYING.**

**THE BENEFIT PROVIDED BY THE TRIGGER VALUE MAY TERMINATE ON THE FINAL REVIEW DATE —**

If the Final Value of either Underlying is less than its Trigger Value and the notes have not been automatically called, the benefit provided by the Trigger Value will terminate and you will be fully exposed to any depreciation of the Lesser Performing Underlying.

PS-5 | Structured Investments

Review Notes Linked to the Lesser Performing of the S&P 500® Index and the SPDR® S&P® Biotech ETF

**THE AUTOMATIC CALL FEATURE MAY FORCE A POTENTIAL EARLY EXIT —**

If your notes are automatically called, the term of the notes may be reduced to as short as approximately one year. There is no guarantee that you would be able to reinvest the proceeds from an investment in the notes at a comparable return for a similar level of risk. Even in cases where the notes are called before maturity, you are not entitled to any fees and commissions described on the front cover of this pricing supplement.

**THE NOTES DO NOT PAY INTEREST.**

**YOU WILL NOT RECEIVE DIVIDENDS ON THE FUND OR THE SECURITIES INCLUDED IN OR HELD BY EITHER UNDERLYING OR HAVE ANY RIGHTS WITH RESPECT TO THE FUND OR THOSE SECURITIES.**

**THERE ARE RISKS ASSOCIATED WITH THE FUND —**

The Fund is subject to management risk, which is the risk that the investment strategies of the Fund's investment adviser, the implementation of which is subject to a number of constraints, may not produce the intended results. These constraints could adversely affect the market price of the shares of the Fund and, consequently, the value of the notes.

**THE PERFORMANCE AND MARKET VALUE OF THE FUND, PARTICULARLY DURING PERIODS OF MARKET VOLATILITY, MAY NOT CORRELATE WITH THE PERFORMANCE OF THE FUND'S UNDERLYING INDEX AS WELL AS THE NET ASSET VALUE PER SHARE —**

The Fund does not fully replicate its Underlying Index (as defined under "The Underlyings" below) and may hold securities different from those included in its Underlying Index. In addition, the performance of the Fund will reflect additional transaction costs and fees that are not included in the calculation of its Underlying Index. All of these factors may lead to a lack of correlation between the performance of the Fund and its Underlying Index. In addition, corporate actions with respect to the equity securities underlying the Fund (such as mergers and spin-offs) may impact the variance between the performances of the Fund and its Underlying Index. Finally, because the shares of the Fund are traded on a securities exchange and are subject to market supply and investor demand, the market value of one share of the Fund may differ from the net asset value per share of the Fund.

During periods of market volatility, securities underlying the Fund may be unavailable in the secondary market, market participants may be unable to calculate accurately the net asset value per share of the Fund and the liquidity of the Fund may be adversely affected. This kind of market volatility may also disrupt the ability of market participants to create and redeem shares of the Fund. Further, market volatility may adversely affect, sometimes materially, the prices at which market participants are willing to buy and sell shares of the Fund. As a result, under these circumstances, the market value of shares of the Fund may vary substantially from the net asset value per share of the Fund. For all of the foregoing reasons, the performance of the Fund may not correlate with the performance of its Underlying Index as well as the net asset value per share of the Fund, which could materially and adversely affect the value of the notes in the secondary market and/or reduce any payment on the notes.

**THE ANTI-DILUTION PROTECTION FOR THE FUND IS LIMITED —**

The calculation agent will make adjustments to the Share Adjustment Factor for certain events affecting the shares of the Fund. However, the calculation agent will not make an adjustment in response to all events that could affect the shares of the Fund. If an event occurs that does not require the calculation agent to make an adjustment, the value of the notes may be materially and adversely affected.

**THE RISK OF THE CLOSING VALUE OF AN UNDERLYING FALLING BELOW ITS TRIGGER VALUE IS GREATER IF THE VALUE OF THAT UNDERLYING IS VOLATILE.**

**LACK OF LIQUIDITY —**

The notes will not be listed on any securities exchange. Accordingly, the price at which you may be able to trade your notes is likely to depend on the price, if any, at which JPMS is willing to buy the notes. You may not be able to sell your notes. The notes are not designed to be short-term trading instruments. Accordingly, you should be able and willing to hold your notes to maturity.

**THE FINAL TERMS AND VALUATION OF THE NOTES WILL BE PROVIDED IN THE PRICING SUPPLEMENT —**

You should consider your potential investment in the notes based on the minimums for the estimated value of the notes and the Call Premium Amounts.

**THE ESTIMATED VALUE OF THE NOTES WILL BE LOWER THAN THE ORIGINAL ISSUE PRICE (PRICE TO PUBLIC) OF THE NOTES —**

The estimated value of the notes is only an estimate determined by reference to several factors. The original issue price of the notes will exceed the estimated value of the notes because costs associated with selling, structuring and hedging the notes are included in the original issue price of the notes. These costs include the selling commissions, the referral fee, the structuring fee, if any, the projected profits, if any, that our affiliates expect to realize for assuming risks inherent in hedging our obligations under the notes and the estimated cost of hedging our obligations under the notes. See “The Estimated Value of the Notes” in this pricing supplement.

**THE ESTIMATED VALUE OF THE NOTES DOES NOT REPRESENT FUTURE VALUES OF THE NOTES AND MAY DIFFER FROM OTHERS’ ESTIMATES —**

See “The Estimated Value of the Notes” in this pricing supplement.

**THE ESTIMATED VALUE OF THE NOTES IS DERIVED BY REFERENCE TO AN INTERNAL FUNDING RATE —**

The internal funding rate used in the determination of the estimated value of the notes is based on, among other things, our and our affiliates’ view of the funding value of the notes as well as the higher issuance, operational and ongoing liability management costs of the notes in comparison to those costs for the conventional fixed-rate debt of JPMorgan Chase & Co. The use of an internal funding rate and any potential changes to that rate may have an adverse effect on the terms of the notes and any secondary market prices of the notes. See “The Estimated Value of the Notes” in this pricing supplement.

PS-6 | Structured Investments

Review Notes Linked to the Lesser Performing of the S&P 500® Index and the SPDR® S&P® Biotech ETF

**THE VALUE OF THE NOTES AS PUBLISHED BY JPMS (AND WHICH MAY BE REFLECTED ON CUSTOMER ACCOUNT STATEMENTS) MAY BE HIGHER THAN THE THEN-CURRENT ESTIMATED VALUE OF THE NOTES FOR A LIMITED TIME PERIOD —**

We generally expect that some of the costs included in the original issue price of the notes will be partially paid back to you in connection with any repurchases of your notes by JPMS in an amount that will decline to zero over an initial predetermined period. See “Secondary Market Prices of the Notes” in this pricing supplement for additional information relating to this initial period. Accordingly, the estimated value of your notes during this initial period may be lower than the value of the notes as published by JPMS (and which may be shown on your customer account statements).

**SECONDARY MARKET PRICES OF THE NOTES WILL LIKELY BE LOWER THAN THE ORIGINAL ISSUE PRICE OF THE NOTES —**

Any secondary market prices of the notes will likely be lower than the original issue price of the notes because, among other things, secondary market prices take into account our internal secondary market funding rates for structured debt issuances and, also, because secondary market prices (a) exclude selling commissions, the referral fee and the structuring fee, if any, and (b) may exclude projected hedging profits, if any, and estimated hedging costs that are included in the original issue price of the notes. As a result, the price, if any, at which JPMS will be willing to buy the notes from you in secondary market transactions, if at all, is likely to be lower than the original issue price. Any sale by you prior to the Maturity Date could result in a substantial loss to you.

**SECONDARY MARKET PRICES OF THE NOTES WILL BE IMPACTED BY MANY ECONOMIC AND MARKET FACTORS —**

The secondary market price of the notes during their term will be impacted by a number of economic and market factors, which may either offset or magnify each other, aside from the selling commissions, referral fee, structuring fee, if any, projected hedging profits, if any, estimated hedging costs and the values of the Underlyings. Additionally, independent pricing vendors and/or third party broker-dealers may publish a price for the notes, which may also be reflected on customer account statements. This price may be different (higher or lower) than the price of the notes, if any, at which JPMS may be willing to purchase your notes in the secondary market. See “Risk Factors — Risks Relating to the Estimated Value and Secondary Market Prices of the Notes — Secondary market prices of the notes will be impacted by many economic and market factors” in the accompanying product supplement.

PS-7 | Structured Investments

Review Notes Linked to the Lesser Performing of the S&P 500<sup>®</sup> Index and the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF

## The Underlyings

The S&P 500<sup>®</sup> Index consists of stocks of 500 companies selected to provide a performance benchmark for the U.S. equity markets. For additional information about the S&P 500<sup>®</sup> Index, see “Equity Index Descriptions — The S&P U.S. Indices” in the accompanying underlying supplement.

The SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF is an exchange-traded fund of the SPDR<sup>®</sup> Series Trust, a registered investment company, that seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index, which we refer to as the Underlying Index with respect to the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF. The Underlying Index for the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF is currently the S&P<sup>®</sup> Biotechnology Select Industry<sup>™</sup> Index. The S&P<sup>®</sup> Biotechnology Select Industry<sup>™</sup> Index is a modified equal-weight index that is designed to measure the performance of the GICS<sup>®</sup> biotechnology sub-industry of the S&P Total Market Index. The S&P<sup>®</sup> Biotechnology Select Industry<sup>™</sup> Index may also include companies in the life sciences tools & services sub-industry of the S&P Total Market Index. For additional information about the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, see “Fund Descriptions — The SPDR<sup>®</sup> S&P<sup>®</sup> Industry ETFs” in the accompanying underlying supplement.

## Historical Information

The following graphs set forth the historical performance of each Underlying based on the weekly historical closing values from January 4, 2013 through November 30, 2018. The closing value of the Index on December 4, 2018 was 2,700.06. The closing value of the Fund on December 4, 2018 was \$80.46. The U.S. equity markets were closed on December 5, 2018 in observance of a National Day of Mourning for former U.S. President George H.W. Bush. We obtained the closing values above and below from the Bloomberg Professional<sup>®</sup> service (“Bloomberg”), without independent verification. The closing values of the Fund above and below may have been adjusted by Bloomberg for actions taken by the Fund, such as stock splits.

The historical closing values of each Underlying should not be taken as an indication of future performance, and no assurance can be given as to the closing value of either Underlying on the Pricing Date or any Review Date. There can be no assurance that the performance of the Underlyings will result in the return of any of your principal amount.

### Historical Performance of the S&P 500<sup>®</sup> Index

**Source: Bloomberg**

PS-8 | Structured Investments

Review Notes Linked to the Lesser Performing of the S&P 500<sup>®</sup> Index and the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF

## **Historical Performance of the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF**

### **Source: Bloomberg**

#### Tax Treatment

You should review carefully the section entitled “Material U.S. Federal Income Tax Consequences” in the accompanying product supplement no. 4-I. The following discussion, when read in combination with that section, constitutes the full opinion of our special tax counsel, Davis Polk & Wardwell LLP, regarding the material U.S. federal income tax consequences of owning and disposing of notes.

Based on current market conditions, in the opinion of our special tax counsel it is reasonable to treat the notes as “open transactions” that are not debt instruments for U.S. federal income tax purposes, as more fully described in “Material U.S. Federal Income Tax Consequences — Tax Consequences to U.S. Holders — Notes Treated as Open Transactions That Are Not Debt Instruments” in the accompanying product supplement. Assuming this treatment is respected, the gain or loss on your notes should be treated as long-term capital gain or loss if you hold your notes for more than a year, whether or not you are an initial purchaser of notes at the issue price. However, the IRS or a court may not respect this treatment, in which case the timing and character of any income or loss on the notes could be materially and adversely affected. In addition, in 2007 Treasury and the IRS released a notice requesting comments on the U.S. federal income tax treatment of “prepaid forward contracts” and similar instruments. The notice focuses in particular on whether to require investors in these instruments to accrue income over the term of their investment. It also asks for comments on a number of related topics, including the character of income or loss with respect to these instruments; the relevance of factors such as the nature of the underlying property to which the instruments are linked; the degree, if any, to which income (including any mandated accruals) realized by non-U.S. investors should be subject to withholding tax; and whether these instruments are or should be subject to the “constructive ownership” regime, which very generally can operate to recharacterize certain long-term capital gain as ordinary income and impose a notional interest charge. While the notice requests comments on appropriate transition rules and effective dates, any Treasury regulations or other guidance promulgated after consideration of these issues could materially and adversely affect the tax consequences of an investment in the notes, possibly with retroactive effect. You should consult your tax adviser regarding the U.S. federal income tax consequences of an investment in the notes, including possible alternative treatments and the issues presented by this notice.

Section 871(m) of the Code and Treasury regulations promulgated thereunder (“Section 871(m)”) generally impose a 30% withholding tax (unless an income tax treaty applies) on dividend equivalents paid or deemed paid to Non-U.S. Holders with respect to certain financial instruments linked to U.S. equities or indices that include U.S. equities. Section 871(m) provides certain exceptions to this withholding regime, including for instruments linked to certain broad-based indices that meet requirements set forth in the applicable Treasury regulations (such an index, a “Qualified Index”). Additionally, a recent IRS notice excludes from the scope of Section 871(m) instruments issued prior to January 1, 2021 that do not have a delta of one with respect to underlying securities that could pay U.S.-source dividends for U.S. federal income tax purposes (each an “Underlying Security”). Based on certain determinations made by us, we expect that Section 871(m) will not apply to the notes with regard to Non-U.S. Holders. Our determination is not binding on the IRS, and the IRS may disagree with this determination. Section 871(m) is complex and its application may depend on your particular circumstances, including whether you enter into other transactions with respect to an Underlying Security. If necessary, further information regarding the potential application of Section 871(m) will be provided in the pricing supplement for the notes. You should consult your tax adviser regarding the

potential application of Section 871(m) to the notes.

PS-9 | Structured Investments

Review Notes Linked to the Lesser Performing of the S&P 500<sup>®</sup> Index and the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF



Withholding under legislation commonly referred to as “FATCA” may (if the notes are recharacterized as debt instruments) apply to amounts treated as interest paid with respect to the notes, as well as to payments of gross proceeds of a taxable disposition, including an automatic call or redemption at maturity, of a note. However, under a 2015 IRS notice, this regime will not apply to payments of gross proceeds (other than any amount treated as interest) with respect to dispositions occurring before January 1, 2019. You should consult your tax adviser regarding the potential application of FATCA to the notes.

#### The Estimated Value of the Notes

The estimated value of the notes set forth on the cover of this pricing supplement is equal to the sum of the values of the following hypothetical components: (1) a fixed-income debt component with the same maturity as the notes, valued using the internal funding rate described below, and (2) the derivative or derivatives underlying the economic terms of the notes. The estimated value of the notes does not represent a minimum price at which JPMS would be willing to buy your notes in any secondary market (if any exists) at any time. The internal funding rate used in the determination of the estimated value of the notes is based on, among other things, our and our affiliates’ view of the funding value of the notes as well as the higher issuance, operational and ongoing liability management costs of the notes in comparison to those costs for the conventional fixed-rate debt of JPMorgan Chase & Co. For additional information, see “Selected Risk Considerations — The Estimated Value of the Notes Is Derived by Reference to an Internal Funding Rate” in this pricing supplement.

The value of the derivative or derivatives underlying the economic terms of the notes is derived from internal pricing models of our affiliates. These models are dependent on inputs such as the traded market prices of comparable derivative instruments and on various other inputs, some of which are market-observable, and which can include volatility, dividend rates, interest rates and other factors, as well as assumptions about future market events and/or environments. Accordingly, the estimated value of the notes is determined when the terms of the notes are set based on market conditions and other relevant factors and assumptions existing at that time.

The estimated value of the notes does not represent future values of the notes and may differ from others’ estimates. Different pricing models and assumptions could provide valuations for the notes that are greater than or less than the estimated value of the notes. In addition, market conditions and other relevant factors in the future may change, and any assumptions may prove to be incorrect. On future dates, the value of the notes could change significantly based on, among other things, changes in market conditions, our or JPMorgan Chase & Co.’s creditworthiness, interest rate movements and other relevant factors, which may impact the price, if any, at which JPMS would be willing to buy notes from you in secondary market transactions.

The estimated value of the notes will be lower than the original issue price of the notes because costs associated with selling, structuring and hedging the notes are included in the original issue price of the notes. These costs include the selling commissions paid to JPMS and other affiliated or unaffiliated dealers, the referral fee paid to an affiliated or unaffiliated dealer, the structuring fee, if any, paid to other affiliated or unaffiliated dealers, the projected profits, if any, that our affiliates expect to realize for assuming risks inherent in hedging our obligations under the notes and the estimated cost of hedging our obligations under the notes. Because hedging our obligations entails risk and may be influenced by market forces beyond our control, this hedging may result in a profit that is more or less than expected, or it may result in a loss. A portion of the profits, if any, realized in hedging our obligations under the notes may be allowed to other affiliated or unaffiliated dealers, and we or one or more of our affiliates will retain any remaining hedging profits. See “Selected Risk Considerations — The Estimated Value of the Notes Will Be Lower Than the Original Issue Price (Price to Public) of the Notes” in this pricing supplement.

#### Secondary Market Prices of the Notes

For information about factors that will impact any secondary market prices of the notes, see “Risk Factors — Risks Relating to the Estimated Value and Secondary Market Prices of the Notes — Secondary market prices of the notes will be impacted by many economic and market factors” in the accompanying product supplement. In addition, we generally expect that some of the costs included in the original issue price of the notes will be partially paid back to you in connection with any repurchases of your notes by JPMS in an amount that will decline to zero over an initial predetermined period. These costs can include projected hedging profits, if any, and, in some circumstances, estimated hedging costs and our internal secondary market funding rates for structured debt issuances. This initial predetermined time period is intended to be the shorter of six months and one-half of the stated term of the notes. The length of any such initial period reflects the structure of the notes, whether our affiliates expect to earn a profit in connection with our hedging activities, the estimated costs of hedging the notes and when these costs are incurred, as determined by our affiliates. See “Selected Risk Considerations — The Value of the Notes as Published by JPMS (and Which May Be Reflected on Customer Account Statements) May Be Higher Than the Then-Current Estimated Value of the Notes for a Limited Time Period” in this pricing supplement.

PS-10 | Structured Investments

[Review Notes Linked to the Lesser Performing of the S&P 500<sup>®</sup> Index and the SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF](#)

### Supplemental Use of Proceeds

The notes are offered to meet investor demand for products that reflect the risk-return profile and market exposure provided by the notes. See “Hypothetical Payout Examples” and “How the Notes Work” in this pricing supplement for an illustration of the risk-return profile of the notes and “The Underlyings” in this pricing supplement for a description of the market exposure provided by the notes.

The original issue price of the notes is equal to the estimated value of the notes plus the selling commissions paid to JPMS and other affiliated or unaffiliated dealers, plus the referral fee paid to an affiliated or unaffiliated dealer, plus the structuring fee, if any, paid to other affiliated or unaffiliated dealers, plus (minus) the projected profits (losses) that our affiliates expect to realize for assuming risks inherent in hedging our obligations under the notes, plus the estimated cost of hedging our obligations under the notes.

### Supplemental Plan of Distribution

We expect that delivery of the notes will be made against payment for the notes on or about the Original Issue Date set forth on the front cover of this pricing supplement, which will be the fifth business day following the Pricing Date of the notes (this settlement cycle being referred to as “T+5”). Under Rule 15c6-1 of the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in two business days, unless the parties to that trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes on any date prior to two business days before delivery will be required to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement and should consult their own advisors.

### Additional Terms Specific to the Notes

You may revoke your offer to purchase the notes at any time prior to the time at which we accept such offer by notifying the applicable agent. We reserve the right to change the terms of, or reject any offer to purchase, the notes prior to their issuance. In the event of any changes to the terms of the notes, we will notify you and you will be asked to accept such changes in connection with your purchase. You may also choose to reject such changes, in which case we may reject your offer to purchase.

You should read this pricing supplement together with the accompanying prospectus, as supplemented by the accompanying prospectus supplement relating to our Series A medium-term notes of which these notes are a part, and the more detailed information contained in the accompanying product supplement and the accompanying underlying supplement. This pricing supplement, together with the documents listed below, contains the terms of the notes and supersedes all other prior or contemporaneous oral statements as well as any other written materials including preliminary or indicative pricing terms, correspondence, trade ideas, structures for implementation, sample structures, fact sheets, brochures or other educational materials of ours. You should carefully consider, among other things, the matters set forth in the “Risk Factors” sections of the accompanying product supplement and the accompanying underlying supplement, as the notes involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisers before you invest in the notes.

**You may access these documents on the SEC website at [www.sec.gov](http://www.sec.gov) as follows (or if such address has changed, by reviewing our filings for the relevant date on the SEC website):**

Product supplement no. 4-I dated April 5, 2018:

[http://www.sec.gov/Archives/edgar/data/19617/000095010318004519/dp87528\\_424b2-ps4i.pdf](http://www.sec.gov/Archives/edgar/data/19617/000095010318004519/dp87528_424b2-ps4i.pdf)

Underlying supplement no. 1-I dated April 5, 2018:

[http://www.sec.gov/Archives/edgar/data/19617/000095010318004514/crt\\_dp87766-424b2.pdf](http://www.sec.gov/Archives/edgar/data/19617/000095010318004514/crt_dp87766-424b2.pdf)

Edgar Filing: JPMORGAN CHASE & CO - Form 424B2

Prospectus supplement and prospectus, each dated April 5, 2018:

[http://www.sec.gov/Archives/edgar/data/19617/000095010318004508/dp87767\\_424b2-ps.pdf](http://www.sec.gov/Archives/edgar/data/19617/000095010318004508/dp87767_424b2-ps.pdf)

Our Central Index Key, or CIK, on the SEC website is 1665650, and JPMorgan Chase & Co.'s CIK is 19617. As used in this pricing supplement, "we," "us" and "our" refer to JPMorgan Financial.

PS-11 | Structured Investments

Review Notes Linked to the Lesser Performing of the S&P 500® Index and the SPDR® S&P® Biotech ETF

25,117

266,480

620,119

507,215

Operating expenses:

Cost of revenue:

Products

116,533

91,530

226,091

180,653

Services

26,446

21,408

45,072

37,491

Total cost of revenue (includes stock-based compensation expense of \$930; \$1,325; \$1,784 and \$2,757 for the three and six months ended May 31, 2011 and 2010, respectively)

142,979

112,938

271,163

218,144

Selling, general and administrative (includes stock-based compensation expense of \$18,361; \$16,315; \$39,605 and \$34,185 for the three and six months ended May 31, 2011 and 2010, respectively)

105,668

89,059

207,440

173,711

Depreciation and amortization

20,714

14,269

38,915

28,099

Restructuring charges (credits)

702

(82  
)

702

(82  
)  
Acquisition-related costs  
1,243

—

4,549

—

Net periodic pension and post-retirement expense  
2,733

1,194

5,465

2,388

Other expense (income), net  
108

(229  
)

613

(1,114  
)  
Total operating expenses  
274,147

217,149

528,847

421,146

Operating income  
50,970

49,331

91,272

86,069

Interest income  
306

94

491

198

Interest expense  
(2,145  
)

(295  
)

(3,807  
)

(660  
)

Non-operating expense, net  
(1,839  
)

(201  
)

(3,316

)

(462

)

Income from continuing operations before income taxes

49,131

49,130

87,956

85,607

Provision for income taxes

(10,401

)

(10,652

)

(18,517

)

(20,180

)

Income from continuing operations

38,730

38,478

69,439

65,427

Loss from discontinued operations, net

(8

)

—

(1

)

(126



)  
Net income  
\$  
38,722

\$  
38,478

\$  
69,438

65,301

Basic earnings per share:

Income from continuing operations  
\$  
0.60

\$  
0.60

\$  
1.07

\$  
1.03

Loss from discontinued operations, net  
\$

—

\$

—

\$

—

\$

—

Net income

\$

0.60

\$

0.60

\$

1.07

\$

1.02

Weighted average shares used in computing basic earnings per share

64,952

63,981

64,784

63,759

Diluted earnings per share:

Income from continuing operations

\$

0.59

\$

0.60

\$

1.06

\$

1.01

Loss from discontinued operations, net

\$

—

\$

—

\$

—

\$

—

Net income

\$

0.59

\$

0.60

\$

1.06

\$

1.01

Weighted average shares used in computing diluted earnings per share

65,547

64,569

65,493

64,498

See accompanying notes.

4

---

Table of Contents

IHS INC.

## CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

	Six Months Ended May 31,	
	2011	2010
	(Unaudited)	
Operating activities:		
Net income	\$69,438	\$65,301
Reconciliation of net income to net cash provided by operating activities:		
Depreciation and amortization	38,915	28,099
Stock-based compensation expense	41,389	36,942
Excess tax benefit from stock-based compensation	(8,412)	(4,674)
Non-cash net periodic pension and post-retirement expense	5,207	1,704
Deferred income taxes	2,981	8,893
Change in assets and liabilities:		
Accounts receivable, net	32,166	21,161
Other current assets	(9,730)	(8,812)
Accounts payable	1,001	1,992
Accrued expenses	(24,365)	(20,260)
Income tax payable	(7,781)	(6,394)
Deferred subscription revenue	60,105	55,951
Other liabilities	67	(747)
Net cash provided by operating activities	200,981	179,156
Investing activities:		
Capital expenditures on property and equipment	(32,531)	(16,339)
Acquisitions of businesses, net of cash acquired	(202,745)	(83,567)
Intangible assets acquired	(2,985)	—
Change in other assets	(2,317)	(943)
Settlements of forward contracts	(3,170)	(1,310)
Net cash used in investing activities	(243,748)	(102,159)
Financing activities:		
Proceeds from borrowings	335,000	75,000
Repayment of borrowings	(334,601)	(43,278)
Payment of debt issuance costs	(6,326)	—
Excess tax benefit from stock-based compensation	8,412	4,674
Proceeds from the exercise of employee stock options	2,144	223
Repurchases of common stock	(22,250)	(22,461)
Net cash provided by (used in) financing activities	(17,621)	14,158
Foreign exchange impact on cash balance	6,767	(12,534)
Net increase (decrease) in cash and cash equivalents	(53,621)	78,621
Cash and cash equivalents at the beginning of the period	200,735	124,201
Cash and cash equivalents at the end of the period	\$147,114	\$202,822

See accompanying notes.

Table of Contents

IHS INC.

## CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

(Unaudited)

(In thousands)

	Shares of Class A Common Stock	Class A Common Stock	Additional Paid-In Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Loss	Total
Balance at November 30, 2010 (Audited)	64,249	\$662	\$541,108	\$(101,554)	\$860,497	\$(124,632)	\$1,176,081
Stock-based award activity	626	10	41,107	(22,250)	—	—	18,867
Excess tax benefit on vested shares	—	—	8,412	—	—	—	8,412
Net income	—	—	—	—	69,438	—	69,438
Other comprehensive income:							
Unrealized losses on hedging activities	—	—	—	—	—	(630)	(630)
Foreign currency translation adjustments	—	—	—	—	—	29,357	29,357
Comprehensive income, net of tax	—	—	—	—	—	—	98,165
Balance at May 31, 2011	64,875	\$672	\$590,627	\$(123,804)	\$929,935	\$(95,905)	\$1,301,525
See accompanying notes.							

Table of Contents

IHS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Basis of Presentation and Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements of IHS Inc. (IHS, we, our, or us) have been prepared on substantially the same basis as our annual consolidated financial statements and should be read in conjunction with our annual report on Form 10-K for the year ended November 30, 2010. In our opinion, these condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows for the periods presented, and such adjustments are of a normal, recurring nature.

Our business has seasonal aspects. For instance, our second quarter results benefit from the inclusion of revenue from CERAWEEK, an annual energy executive gathering. In addition, every three years, our third quarter benefits from the inclusion of revenue generated by the triennial release of the Boiler Pressure Vessel Code (BPVC) engineering standard. The BPVC benefit most recently occurred in the third quarter of 2010. Our fourth quarter revenues and profits are modestly higher than the other three quarters; we attribute that trend to non-subscription revenue increases that tend to occur towards year-end.

Recent Accounting Pronouncements

In October 2009, the FASB issued guidance on revenue recognition that became effective for us in the first quarter of 2011. Under the new guidance, when vendor specific objective evidence (VSOE) or third party evidence for deliverables in an arrangement cannot be determined, a best estimate of the selling price is required to separate deliverables and allocate arrangement consideration using the relative selling price method. The new guidance includes new disclosure requirements on how the application of the relative selling price method affects the timing and amount of revenue recognition. The adoption of the update did not have a material impact on our financial position or results of operations.

2. Business Combinations

During the six months ended May 31, 2011, we completed the following acquisitions, among others:

ODS-Petrodata (Holdings) Ltd. (ODS-Petrodata). On April 16, 2011, we acquired ODS-Petrodata for approximately \$75 million, net of cash acquired. ODS-Petrodata is a premier provider of data, information, and market intelligence to the offshore energy industry. We preliminarily recorded approximately \$22 million of finite-lived intangible assets and \$62 million of goodwill as a result of the transaction.

Dyadem International, Ltd. (Dyadem). On April 26, 2011, we acquired Dyadem for approximately \$52 million, net of cash acquired. Dyadem is a market leader in Operational Risk Management and Quality Risk Management solutions. We preliminarily recorded \$31 million of finite-lived intangible assets and \$23 million of goodwill as a result of the transaction.

Chemical Market Associates, Inc. (CMAI). On May 2, 2011, we acquired CMAI for approximately \$73 million, net of cash acquired. CMAI is a leading provider of market and business advisory services for the worldwide petrochemical, specialty chemicals, fertilizer, plastics, fibers, and chlor-alkali industries. We preliminarily recorded approximately \$37 million of finite-lived intangible assets and \$61 million of goodwill as a result of the transaction.

3. Commitments and Contingencies

We are a party to various legal proceedings that arise in the ordinary course of business. In the opinion of management, none of these actions, either individually or in the aggregate, is expected to have a material adverse affect on our financial condition, liquidity, or results of operations.

#### 4. Comprehensive Income

Our comprehensive income for the three and six months ended May 31, 2011 and 2010, was as follows:

7

---



Table of Contents

	Three Months Ended May 31,		Six Months Ended May 31,	
	2011	2010	2011	2010
	(In thousands)			
Net income	\$38,722	\$38,478	\$69,438	\$65,301
Other comprehensive income (loss):				
Unrealized losses on hedging activities	(630	) —	(630	) —
Foreign currency translation adjustment	5,941	(16,680	) 29,357	(43,248
Total comprehensive income	\$44,033	\$21,798	\$98,165	\$22,053

## 5. Discontinued Operations

Effective December 31, 2009, we sold our small non-core South African business for approximately \$2 million with no gain or loss on sale. The sale of this business included a building and certain intellectual property. In exchange for the sale of these assets, we received two three-year notes receivable, one secured by a mortgage on the building and the second secured by a pledge on the shares of the South African company. In December 2010, we received full payment of the note receivable that was secured by a mortgage on the building. Operating results of the discontinued operations for the three months ended May 31, 2011 and 2010, respectively, were as follows:

	Three Months Ended May 31,		Six Months Ended May 31,	
	2011	2010	2011	2010
	(In thousands)			
Loss from discontinued operations	\$(12	) \$—	\$(1	) \$(159
Tax benefit	4	—	—	33
Loss from discontinued operations, net	\$(8	) \$—	\$(1	) \$(126

## 6. Acquisition-related Costs

During the first and second quarters of 2011, we incurred acquisition-related costs to close deals and leverage synergies from recent business combinations. As a result, we eliminated approximately 25 positions and closed one of the acquired offices. The changes only affected the Americas and EMEA segments.

The acquisition-related charges that we have recorded consists of direct and incremental costs associated with severance, outplacement, and other employee-related benefits; facility closure costs; and legal, due diligence, and valuation service fees associated with the recent acquisitions that were incurred during the six months of 2011. Approximately \$4.1 million of the charge related to our Americas segment and \$0.4 million pertained to our EMEA segment. The charge was comprised of the following:

	Three Months Ended February 28, 2011	Three Months Ended May 31, 2011	Six Months Ended May 31, 2011
	(In thousands)		
Employee severance and other termination benefits	\$2,280	\$—	\$2,280
Contract termination costs	606	—	606
Other	420	1,243	1,663
Total	\$3,306	\$1,243	\$4,549

A reconciliation of the related accrued liability as of May 31, 2011 was as follows:

Table of Contents

	Employee Severance and Other Termination Benefits (In thousands)	Contract Termination Costs	Other	Total
Balance at November 30, 2010	\$—	\$—	\$—	\$—
Add: Costs incurred	2,280	606	1,663	4,549
Less: Amount paid during the six months ended May 31, 2011	(2,212	) (35	) (1,435	) (3,682
Balance at May 31, 2011	\$68	\$571	\$228	\$867

As of May 31, 2011, the entire remaining \$0.9 million liability was in the Americas segment.

## 7. Restructuring Charge

During the third quarter of 2010, we announced various plans to streamline operations and merge functions. As a result, we reduced our aggregate workforce by approximately 3% and consolidated several locations. The changes primarily affected the Americas and EMEA segments.

The restructuring charge that we recorded consisted of direct and incremental costs associated with restructuring and related activities, including severance, outplacement and other employee related benefits; facility closures and relocations; and legal expenses associated with employee terminations incurred during the quarter. The entire \$9.1 million restructuring charge was recorded during the third quarter of 2010. Approximately \$7.7 million of the charge related to our Americas segment and \$1.3 million pertained to our EMEA segment, with the remainder in APAC. The restructuring charge was comprised of the following (in thousands):

Employee severance and other termination benefits	\$8,024
Contract termination costs	972
Other	108
Total	\$9,104

In the second quarter of 2011, we recorded an additional \$0.7 million of net restructuring costs in the Americas segment, which represents a revision to our third quarter 2010 estimate of cost to exit space in one of our facilities, partially offset by favorable resolution of employee severance costs. The following table provides a reconciliation of the restructuring liability as of May 31, 2011:

	Employee Severance and Other Termination Benefits (In thousands)	Contract Termination Costs	Other	Total
Balance at November 30, 2010	\$1,286	\$122	\$47	\$1,455
Add: Restructuring costs incurred	—	—	—	—
Less: Amount paid during the six months ended May 31, 2011	(892	) (1,015	) —	) (1,907
Revision to prior estimates	\$(394	) \$1,143	\$(47	) \$702
Balance at May 31, 2011	\$—	\$250	\$—	\$250

As of May 31, 2011, the entire remaining \$0.3 million liability was in the Americas segment.

## 8. Stock-based Compensation

A little more than a third of our nonvested shares have performance-based vesting provisions. We evaluate our performance-based vesting awards each quarter to identify any required adjustments to the expected vesting schedule, remaining unrecognized compensation cost, and stock-based compensation expense. Stock-based compensation expense for the three and six months ended May 31, 2011 and 2010, respectively, was as follows:

9

---

Table of Contents

	Three Months Ended May 31,		Six Months Ended May 31,	
	2011	2010	2011	2010
	(In thousands)			
Cost of revenue	\$930	\$1,325	\$1,784	\$2,757
Selling, general and administrative	18,361	16,315	39,605	34,185
Total stock-based compensation expense	\$19,291	\$17,640	\$41,389	\$36,942
Total income tax benefits recognized for stock-based compensation arrangements were as follows:				
	Three Months Ended May 31,		Six Months Ended May 31,	
	2011	2010	2011	2010
	(In thousands)			
Income tax benefits	\$6,815	\$6,527	\$14,602	\$13,669

No stock-based compensation cost was capitalized during the three or six months ended May 31, 2011 and 2010.

As of May 31, 2011, there was \$116.9 million of unrecognized compensation cost, adjusted for estimated forfeitures, related to nonvested stock-based awards that will be recognized over a weighted average period of approximately 1.5 years. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures.

Nonvested Shares. The following table summarizes changes in nonvested shares during the six months ended May 31, 2011.

	Shares	Weighted- Average Grant Date Fair Value
	(in thousands)	
Balances, November 30, 2010	2,732	\$48.40
Granted	1,119	\$80.47
Vested	(840)	) \$53.12
Forfeited	(105)	) \$53.90
Balances, May 31, 2011	2,906	\$63.46

The total fair value of nonvested shares that vested during the six months ended May 31, 2011 was \$67.8 million based on the weighted-average fair value on the vesting date and \$44.6 million based on the weighted-average fair value on the grant date.

## 9. Income Taxes

Our effective tax rate is estimated based upon the effective tax rate expected to be applicable for the full fiscal year. Our effective tax rate for the three and six months ended May 31, 2011 was 21.2% and 21.1% , respectively, compared to 21.7% and 23.6% for the same respective periods of 2010. The 2011 effective tax rates reflect the full-year benefit from a tax election made during the second quarter of 2010.

As of May 31, 2011, the total amount of unrecognized tax benefits was \$1.8 million, of which \$0.2 million related to interest. Unrecognized tax benefits increased less than \$0.1 million during the first six months of 2011.

## 10. Debt

On January 5, 2011, we entered into a \$1 billion syndicated bank credit facility consisting of a \$300 million term loan and a \$700 million revolver (collectively, the Credit Facility). All borrowings under the Credit Facility are unsecured. The loan and revolver included in the Credit Facility have a five-year term ending in January 2016. The interest rates for borrowings under the Credit Facility will be the applicable LIBOR plus 1.25% to 2.00%, depending upon our Leverage Ratio, which is defined as the ratio of Consolidated Funded Indebtedness to rolling four-quarter Consolidated Earnings Before Interest Expense, Taxes, Depreciation and Amortization (EBITDA), as defined in the Credit Facility. A commitment fee on any unused balance is payable periodically and ranges from 0.20% to 0.35% based upon our Leverage Ratio. The Credit Facility contains certain financial and other covenants, including a

maximum Leverage Ratio and a maximum Interest Coverage Ratio, as defined in the Credit Facility. The old revolving credit agreement was retired immediately upon consummation of the new financing.

Table of Contents

As of May 31, 2011, we were in compliance with all of the covenants in the Credit Facility and had \$293 million of outstanding borrowings under the agreement at a current annual interest rate of 1.56%. We also had approximately \$0.4 million of outstanding letters of credit under the agreement as of May 31, 2011.

Our debt as of May 31, 2011 also included approximately \$2 million of non-interest bearing notes that were issued to the sellers of Prime Publications Limited, a company that we purchased in 2008. These notes are due upon demand and are therefore recorded in short-term debt in the consolidated balance sheets.

## 11. Pensions and Post-retirement Benefits

Our defined-benefit plans consist of a non-contributory retirement plan for all of our U.S. employees with at least one year of service (U.S. RIP), a pension plan that covers certain employees of one of our United Kingdom-based subsidiaries (U.K. RIP), and a supplemental income plan (SIP) for certain US employees who earn over a federally stipulated amount. During 2010, we approved a plan design change to the U.S. RIP that was effective March 1, 2011, and we also made the decision to discontinue future benefit accruals under the U.K. RIP. Our net periodic pension expense (income) for the three and six months ended May 31, 2011 and 2010, respectively, was comprised of the following:

	Three Months Ended May 31, 2011				Three Months Ended May 31, 2010			
	U.S. RIP	U.K. RIP	SIP	Total	U.S. RIP	U.K. RIP	SIP	Total
	(In thousands)							
Service costs incurred	2,110	\$36	\$35	\$2,181	\$2,004	\$158	\$53	2,215
Interest costs on projected benefit obligation	2,969	489	99	3,557	2,993	440	104	3,537
Expected return on plan assets	(4,830)	(591)	—	(5,421)	(5,038)	(530)	—	(5,568)
Amortization of prior service cost	(336)	—	(2)	(338)	(119)	—	11	(108)
Amortization of actuarial loss (gain)	2,463	10	42	2,515	1,497	49	46	1,592
Amortization of transitional obligation/(asset)	—	—	11	11	—	—	10	10
Net periodic pension expense (income)	\$2,376	\$(56)	\$185	\$2,505	\$1,337	\$117	\$224	\$1,678

Table of Contents

	Six Months Ended May 31, 2011				Six Months Ended May 31, 2010			
	U.S. RIP	U.K. RIP	SIP	Total	U.S. RIP	U.K. RIP	SIP	Total
	(In thousands)							
Service costs incurred	4,219	\$73	\$70	\$4,362	\$4,008	\$319	\$106	4,433
Interest costs on projected benefit obligation	5,938	985	198	7,121	5,986	890	208	7,084
Expected return on plan assets	(9,660 )	(1,190 )	—	(10,850 )	(10,076 )	(1,071 )	—	(11,147 )
Amortization of prior service cost	(672 )	—	(4 )	(676 )	(238 )	—	22	(216 )
Amortization of actuarial loss (gain)	4,926	20	84	5,030	2,993	99	91	3,183
Amortization of transitional obligation/(asset)	—	—	22	22	—	—	20	20
Net periodic pension expense (income)	\$4,751	\$(112 )	\$370	\$5,009	\$2,673	\$237	\$447	\$3,357

Our net periodic post-retirement expense (income) was comprised of the following for the three and six months ended May 31, 2011 and 2010, respectively:

	Three Months Ended May 31,		Six Months Ended May 31,	
	2011	2010	2011	2010
	(In thousands)			
Service costs incurred	\$7	\$12	\$14	\$24
Interest costs on projected benefit obligation	132	140	264	280
Amortization of prior service cost	(81 )	(808 )	(162 )	(1,616 )
Amortization of net actuarial loss	170	172	340	343
Net periodic post-retirement expense (income)	\$228	\$(484 )	\$456	\$(969 )

## 12. Earnings per Share

Basic earnings per share (EPS) is computed on the basis of the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common shares.

Weighted average common shares outstanding for the three and six months ended May 31, 2011 and 2010, respectively, were calculated as follows:

	Three Months Ended May 31,		Six Months Ended May 31,	
	2011	2010	2011	2010
	(In thousands)			
Weighted average common shares outstanding:				
Shares used in basic EPS calculation	64,952	63,981	64,784	63,759
Effect of dilutive securities:				
Restricted stock units	551	449	659	603

Edgar Filing: JPMORGAN CHASE & CO - Form 424B2

Stock options and other stock-based awards	44	139	50	136
Shares used in diluted EPS calculation	65,547	64,569	65,493	64,498

13. Derivatives

12

---



Table of Contents

In April 2011, to mitigate interest rate exposure on our \$300 million term loan, we entered into an interest rate derivative contract that effectively swaps \$50 million of floating rate debt for fixed rate debt. Because the terms of the swap and the variable rate debt coincide, we do not expect any ineffectiveness. We have designated and accounted for this instrument as a cash flow hedge, with changes in fair value being deferred in accumulated other comprehensive loss in the consolidated balance sheets.

Since our swap is not listed on an exchange, we have evaluated its fair value by reference to similar transactions in active markets; consequently, we have classified the swap within Level 2 of the fair value measurement hierarchy. As of May 2011, the fair market value of our swap was a loss of \$1.0 million, and the current mark-to-market loss position is recorded in other accrued expenses in the consolidated balance sheets.

In June 2011, we entered into a second \$50 million interest rate derivative contract with the same terms and maturity date as the initial swap described above.

## 14. Goodwill and Intangible Assets

The following table presents details of our intangible assets, other than goodwill, as of May 31, 2011 and November 30, 2010:

	As of	May 31, 2011		As of	November 30, 2010	
	Gross	Accumulated Amortization	Net	Gross	Accumulated Amortization	Net
	(In thousands)					
Intangible assets subject to amortization:						
Information databases	\$273,035	\$(91,049)	) \$181,986	\$237,888	\$(73,815)	) \$164,073
Customer relationships	168,629	(34,595)	) 134,034	132,878	(28,533)	) 104,345
Non-compete agreements	9,868	(7,110)	) 2,758	9,551	(5,934)	) 3,617
Developed computer software	75,099	(19,964)	) 55,135	52,258	(15,926)	) 36,332
Other	16,050	(13,403)	) 2,647	14,944	(10,273)	) 4,671
Total	\$542,681	\$(166,121)	) \$376,560	\$447,519	\$(134,481)	) \$313,038
Intangible assets not subject to amortization:						
Trademarks	75,356	—	) 75,356	70,366	—	) 70,366
Perpetual licenses	1,230	—	) 1,230	1,164	—	) 1,164
Total intangible assets	\$619,267	\$(166,121)	) \$453,146	\$519,049	\$(134,481)	) \$384,568

Intangible assets amortization expense was \$14.5 million for the three months and \$27.6 million for the six months ended May 31, 2011, as compared with \$9.8 million for the three months and \$19.1 million for the six months ended May 31, 2010. The following table presents the estimated future amortization expense related to intangible assets held as of May 31, 2011:

Year	Amount (in thousands)
Remainder of 2011	\$31,587
2012	63,004
2013	57,696
2014	48,120

2015

44,900

Changes in our goodwill and gross intangible assets from November 30, 2010 to May 31, 2011 were primarily the result of our recent acquisition activities, in addition to foreign currency translation. Net intangibles increased primarily because of the addition of intangible assets associated with the acquisitions.

#### 15. Segment Information

13

---

Table of Contents

We prepare our financial reports and analyze our business results within our three reportable geographic segments: Americas, EMEA, and APAC. We evaluate segment performance primarily at the revenue and operating profit level for each of these three segments. We also evaluate revenues by transaction type and information domain.

As our APAC operations have evolved, the management structure of the region has also evolved and now includes responsibility for overseeing India. Accordingly, we have included India's 2011 results in the APAC geographic segment, and we have reclassified India's 2010 results from EMEA to APAC.

Information about the operations of our three segments is set forth below. No single customer accounted for 10% or more of our total revenue for the three and six months ended May 31, 2011 and 2010. There are no material inter-segment revenues for any period presented. Certain corporate transactions are not allocated to the reportable segments, including such items as stock-based compensation expense, net periodic pension and post-retirement expense (income), corporate-level impairments, and gain (loss) on sale of corporate assets.

	Americas	EMEA	APAC	Shared Services	Consolidated Total
	(In thousands)				
Three Months Ended May 31, 2011					
Revenue	\$ 196,559	\$ 95,628	\$ 32,930	\$—	\$ 325,117
Operating income	54,786	19,614	9,865	(33,295)	) 50,970
Depreciation and amortization	15,319	4,798	47	550	20,714
Three Months Ended May 31, 2010					
Revenue	\$ 168,054	\$ 75,248	\$ 23,178	\$—	\$ 266,480
Operating income	54,430	17,312	7,875	(30,286)	) 49,331
Depreciation and amortization	9,955	3,758	25	531	14,269

	Americas	EMEA	APAC	Shared Services	Consolidated Total
	(In thousands)				
Six Months Ended May 31, 2011					
Revenue	\$ 377,750	\$ 180,066	\$ 62,303	\$—	\$ 620,119
Operating income	104,105	36,111	18,126	(67,070)	) 91,272
Depreciation and amortization	29,428	8,290	86	1,111	38,915
Six Months Ended May 31, 2010					
Revenue	\$ 320,022	\$ 143,444	\$ 43,749	\$—	\$ 507,215
Operating income	101,098	29,993	14,176	(59,198)	) 86,069
Depreciation and amortization	19,171	7,818	50	1,060	28,099

Revenue by transaction type was as follows:

	Three Months Ended May 31,		Six Months Ended May 31,	
	2011	2010	2011	2010
	(In thousands)			
Subscription revenue	\$ 250,541	\$ 205,722	\$ 484,313	\$ 401,208
Consulting revenue	18,953	15,085	35,469	26,970
Transaction revenue	14,327	12,235	27,665	23,625
Other revenue	41,296	33,438	72,672	55,412
Total revenue	\$ 325,117	\$ 266,480	\$ 620,119	\$ 507,215

Revenue by information domain was as follows:



Table of Contents

	Three Months Ended May 31,		Six Months Ended May 31,	
	2011	2010	2011	2010
	(In thousands)			
Energy revenue	\$139,445	\$123,114	\$261,096	\$233,049
Product Lifecycle (PLC) revenue	108,493	83,175	210,273	157,909
Security revenue	30,111	26,953	56,931	52,352
Environment revenue	22,568	13,391	43,543	24,598
Macroeconomic Forecasting and Intersection revenue	24,500	19,847	48,276	39,307
Total revenue	\$325,117	\$266,480	\$620,119	\$507,215

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

In addition to historical information, this quarterly report on Form 10-Q contains forward-looking statements. These forward-looking statements generally are identified by the use of the words "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," or "continue," the negative of these terms, and other similar expressions. Forward-looking statements are based on current expectations, assumptions, and projections that are subject to risks and uncertainties, which may cause actual results to differ materially from the forward-looking statements. A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from such forward-looking statements is outlined under the "Risk Factors" section of our 2010 annual report on Form 10-K. We are under no obligation to update or publicly revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Management's discussion and analysis is intended to help the reader understand the financial condition and results of operations for IHS Inc. The following discussion should be read in conjunction with our annual report on Form 10-K for the year ended November 30, 2010, the Condensed Consolidated Financial Statements and accompanying notes included in this quarterly report on Form 10-Q, and important information and disclosure that we routinely post to our website ([www.ihs.com](http://www.ihs.com)).

## Executive Summary

## Business Overview

IHS is a leading source of information and insight in critical areas that shape today's business landscape, including energy and power; design and supply chain; defense, risk and security; environmental, health and safety (EHS) and sustainability; country and industry forecasting; and commodities, pricing and cost. Businesses and governments around the globe rely on the comprehensive content, expert independent analysis and flexible delivery methods of IHS to make high-impact decisions and develop strategies with speed and confidence. IHS has been in business since 1959 and became a publicly traded company on the New York Stock Exchange in 2005. Headquartered in Englewood, Colorado, USA, IHS employs more than 5,100 people in more than 30 countries around the world. We source raw data and transform it into information through a series of transformational steps that reduce the uncertainty that is inherent in unrefined data and enhances its usefulness.

Inherent in all of our strategies is a firm commitment to put our customers first in everything that we do. We believe that maintaining a disciplined "outside-in" approach will allow us to better serve our customers and our shareholders. To achieve that goal, we have organized our business around our customers and the geographies in which they reside: Americas, EMEA, and APAC. This structure allows us to tailor and expand the solutions we offer to meet the unique needs of our customers both globally and in local markets.

We sell our offerings primarily through subscriptions, which tend to generate recurring revenue and cash flow for us. Our subscriptions are usually for one-year periods, and we have historically seen high renewal rates. Subscriptions are generally paid in full within one or two months after the subscription period commences; as a result, the timing of our cash flows generally precedes the recognition of revenue and income.

Our business has seasonal aspects. For instance, our second quarter results benefit from the inclusion of revenue from CERAWEEK, an annual energy executive gathering. In addition, every three years, our third quarter benefits from the inclusion of revenue generated by the triennial release of the Boiler Pressure Vessel Code (BPVC) engineering standard. The BPVC benefit most recently occurred in the third quarter of 2010. Fourth quarter revenues and profits are modestly higher than the other three quarters; we attribute that trend to non-subscription revenue increases that tend to occur towards year-end.

## Table of Contents

### Global Operations

Approximately 50% of our revenue is transacted outside of the United States; however, only about 30% of our revenue is transacted in currencies other than the U.S. dollar. As a result, a strengthening U.S. dollar relative to certain currencies has a negative impact on our revenue; conversely, a weakening U.S. dollar has a positive impact on our revenue. However, the impact on operating income is diminished due to certain operating expenses denominated in currencies other than the U.S. dollar. Our largest foreign currency exposures, in order of magnitude, are the British Pound, the Canadian Dollar, and the Euro.

### Key Performance Indicators

We believe that revenue growth, Adjusted EBITDA (both in dollars and margin), and free cash flow are the key measures of our success. Adjusted EBITDA and free cash flow are non-GAAP financial measures (as defined by the rules of the Securities and Exchange Commission) that are further discussed in the following paragraphs.

**Revenue growth.** We review year-over-year revenue growth in our segments as a key measure of our success in addressing customer needs in each region of the world. We measure revenue growth in terms of organic, acquisitive, and foreign currency impacts. We define these components as follows:

**Organic** – We define organic revenue growth as total revenue growth due to all factors other than acquisitions and foreign currency. We drive this type of revenue growth through value realization (pricing), expanding wallet share of existing customers through up-selling and cross-selling efforts, securing new customer business, and through the sale of new offerings.

**Acquisitive** – We define acquisition-related revenue as the revenue generated from acquired products and services from the date of acquisition to the first anniversary date of that acquisition. This type of growth comes as a result of our strategy to purchase, integrate, and leverage the value of assets we acquire.

**Foreign currency** – We define the foreign currency impact on revenue as the difference between current revenue at current exchange rates and current revenue at the corresponding prior period exchange rates. Due to the significance of revenue transacted in foreign currencies, we measure the impact of foreign currency movements on revenue.

**Non-GAAP measures.** We use non-GAAP measures such as Adjusted EBITDA and free cash flow in our operational and financial decision-making, believing that such measures allow us to focus on what we deem to be more reliable indicators of ongoing operating performance (Adjusted EBITDA) and our ability to generate cash flow from operations (free cash flow). We also believe that investors may find non-GAAP financial measures useful for the same reasons, although we caution readers that non-GAAP financial measures are not a substitute for GAAP financial measures or disclosures. None of these non-GAAP financial measures are recognized terms under GAAP and do not purport to be an alternative to net income or operating cash flow as an indicator of operating performance or any other GAAP measure. Throughout this section on management's discussion and analysis and on our IHS website, we provide reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures.

**Adjusted EBITDA.** EBITDA and Adjusted EBITDA are used by many of our investors, research analysts, investment bankers, and lenders to assess our operating performance. For example, a measure similar to EBITDA is required by the lenders under our term loan and revolving credit agreement. We define EBITDA as net income plus or minus net interest, plus provision for income taxes, depreciation, and amortization. Our definition of Adjusted EBITDA further excludes (i) non-cash items (e.g., stock-based compensation expense and non-cash pension and post-retirement expense) and (ii) items that management does not consider to be useful in assessing our operating performance (e.g.,

acquisition-related costs, restructuring charges, income or loss from discontinued operations, and gain or loss on sale of assets).

Free Cash Flow. We define free cash flow as net cash provided by operating activities less capital expenditures.

Because not all companies use identical calculations, our presentation of non-GAAP financial measures may not be comparable to other similarly titled measures of other companies. However, these measures can still be useful in evaluating our performance against our peer companies because we believe the measures provide users with valuable insight into key components of GAAP financial disclosures. For example, a company with higher GAAP net income may not be as appealing to investors if its net income is more heavily comprised of gains on asset sales. Likewise, eliminating the effects of interest



Table of Contents

income and expense moderates the impact of a company's capital structure on its performance.

## Results of Operations

## Total Revenue

Second quarter 2011 revenue increased 22% compared to the second quarter of 2010, and our year-to-date 2011 revenue also increased 22% compared to the same period of 2010. The table below displays the percentage point change in revenue due to organic, acquisitive, and foreign currency factors when comparing the three and six months ended May 31, 2011 to the three and six months ended May 31, 2010.

(All amounts represent percentage points)	Three Month Change			Six Month Change			
	Organic	Acquisitive	Foreign Currency	Organic	Acquisitive	Foreign Currency	
Increase in total revenue	7	% 13	% 3	% 8	% 13	% 2	%

The 7% organic revenue growth for the second quarter of 2011 was broad-based in nature, with most transaction types and all domains contributing to the growth. We experienced an 8% organic revenue increase in our subscription-based business, which continues to demonstrate the strength of the subscription-based business. We also benefited from positive organic growth within the transaction and other categories of our non-subscription business, which led to a combined 3% organic growth rate for the non-subscription business in the second quarter of 2011.

The 8% organic revenue growth for the six months of 2011 was also broad-based in nature, with all transaction types and all domains contributing to the growth. The subscription-based business increased 8% organically, and the non-subscription businesses all contributed positively to the overall growth.

The acquisition-related revenue growth for the quarter and year-to-date periods was primarily due to acquisitions we have made in the last twelve months, including the following:

Quantitative Micro Software (QMS) in the second quarter of 2010;

Certain chemical and energy portfolio business assets of Access Intelligence, as well as the acquisition of Atrion International Inc.; Syntex Management Systems, Inc.; and iSuppli Inc. in the fourth quarter of 2010; and

ODS-Petrodata; Dyadem International, Ltd.; and Chemical Market Associates, Inc. in the second quarter of 2011.

We evaluate revenue by segment in order to better understand our customers' needs in the geographies where they reside. We also supplementally review revenue by transaction type and information domain. Understanding revenue by transaction type helps us identify changes related to recurring revenue and product margin, while revenue by information domain helps us understand performance based on our defined capabilities.

## Revenue by Segment (geography)

(In thousands, except percentages)	Three Months Ended May 31,			Percentage Change	Six Months Ended May 31,			
	2011	2010			2011	2010	Percentage Change	
Americas revenue	\$ 196,559	\$ 168,054	17	%	\$ 377,750	\$ 320,022	18	%
As a percent of total revenue	60	% 63	%		61	% 63	%	
EMEA revenue	95,628	75,248	27	%	180,066	143,444	26	%
As a percent of total revenue	29	% 28	%		29	% 28	%	
APAC revenue	32,930	23,178	42	%	62,303	43,749	42	%
As a percent of total revenue	10	% 9	%		10	% 9	%	
Total revenue	\$ 325,117	\$ 266,480	22	%	\$ 620,119	\$ 507,215	22	%

The percentage change in each geography segment is due to the factors described in the following table.

17

---

Table of Contents

(All amounts represent percentage points)	Three Month Change			Six Month Change			Foreign Currency
	Organic	Acquisitive	Foreign Currency	Organic	Acquisitive	Foreign Currency	
Americas revenue	6	% 10	% 1	% 7	% 10	% 1	%
EMEA revenue	5	% 16	% 6	% 7	% 16	% 3	%
APAC revenue	19	% 19	% 4	% 17	% 22	% 3	%

As our APAC operations have evolved, the management structure of the region has also evolved and now includes responsibility for overseeing India. Accordingly, we have included India's 2011 results in the APAC geographic segment, and we have reclassified India's 2010 results from EMEA to APAC.

For the three and six months of 2011, we experienced broad-based organic revenue growth in all three geographies, with subscription-based revenue and Energy domain revenue providing key contributions to the growth.

## Revenue by Transaction Type

(In thousands, except percentages)	Three Months Ended May 31,			Percentage Change	Six Months Ended May 31,			Percentage Change
	2011	2010			2011	2010		
Subscription revenue	\$250,541	\$205,722	22	%	\$484,313	\$401,208	21	%
As a percent of total revenue	77	% 77	%		78	% 79	%	
Consulting revenue	18,953	15,085	26	%	35,469	26,970	32	%
As a percent of total revenue	6	% 6	%		6	% 5	%	
Transaction revenue	14,327	12,235	17	%	27,665	23,625	17	%
As a percent of total revenue	4	% 5	%		4	% 5	%	
Other revenue	41,296	33,438	24	%	72,672	55,412	31	%
As a percent of total revenue	13	% 13	%		12	% 11	%	
Total revenue	\$325,117	\$266,480	22	%	\$620,119	\$507,215	22	%

We summarize our transaction type revenue by the following categories:

Subscription revenue represents the significant majority of our revenue, and is comprised of subscriptions to our various information databases.

Consulting revenue represents customer relationships where we are engaged to perform various professional services such as research and analysis, modeling and forecasting, and other similar work. Our consulting offerings are primarily focused on Energy/Resources, Manufacturing/Services, and the Public Sector.

Transaction revenue represents single-document product sales, which are typically sold through ecommerce and telesales channels. We usually deliver these products to our customers as part of a one-time, unique sale.

Other revenue consists of a variety of revenue streams, including conferences and events, advertising, data storage services, parts optimization software and services, and Environmental, Health, and Safety (EHS) & Sustainability enterprise software sales and services.

Relative to the 22% subscription revenue growth for the second quarter, approximately 8% is due to organic growth. This trend is especially important for us, as 77% of our revenue currently comes from our subscription base. Each of the three components of our non-subscription business also contributed positively to the overall revenue growth, with a combined 3% organic growth rate. While the three points of growth reduced the overall growth rate of the company, it is the fourth consecutive quarter of positive organic growth for our non-subscription business. Our CERAWEEK conference showed nice growth over the prior year, representative of the strength in our Energy end market.

Relative to the 21% subscription revenue growth for the six months of 2011, approximately 8% is due to organic growth. Year-to-date, all three components of the non-subscription part of the business had positive organic growth, which signals to us that our business is experiencing steady growth in all areas. We think it is important to understand that our non-subscription products and services are critical to us, as they complement our subscription business in creating strong and comprehensive customer relationships.

Revenue by Information Domain

18

---

Table of Contents

(In thousands, except percentages)	Three Months Ended May 31,			Percentage Change	Six Months Ended May 31,			Percentage Change
	2011	2010			2011	2010		
Energy revenue	\$139,445	\$123,114	13	%	\$261,096	\$233,049	12	%
As a percent of total revenue	43	% 46	%		42	% 46	%	
Product Lifecycle (PLC) revenue	108,493	83,175	30	%	210,273	157,909	33	%
As a percent of total revenue	33	% 31	%		34	% 31	%	
Security revenue	30,111	26,953	12	%	56,931	52,352	9	%
As a percent of total revenue	9	% 10	%		9	% 10	%	
Environment revenue	22,568	13,391	69	%	43,543	24,598	77	%
As a percent of total revenue	7	% 5	%		7	% 5	%	
Macroeconomic Forecasting and Intersection revenue	24,500	19,847	23	%	48,276	39,307	23	%
As a percent of total revenue	8	% 7	%		8	% 8	%	
Total revenue	\$325,117	\$266,480	22	%	\$620,119	\$507,215	22	%

For the three and six months of 2011, our Energy domain revenue is still our most significant source of revenue, and our revenue growth in that domain highlights the continued strength of our Energy offerings across all geographic segments. Product Lifecycle revenue increases were primarily due to the fourth quarter 2010 acquisition of iSuppli, as well as steady performance in the other PLC offerings. Security revenue continues to be particularly strengthened by our maritime offerings. Environment's increases are primarily due to recent acquisitions, with solid organic growth contributing to the increase as well. The Macroeconomic Forecasting and Intersection revenue supports all of the other domains, and has experienced double digit organic growth in both the three and six months of 2011.

## Operating Expenses

We continuously evaluate our operating expenses and look for opportunities to improve margins and manage expenses. In 2010, we eliminated approximately three percent of our worldwide workforce. In the first and second quarters of 2011, we incurred acquisition-related costs to close deals and leverage synergies from recent business combinations. We continue to make progress on our Vanguard initiative, which is our plan for consolidating and standardizing billing systems, general ledgers, sales-force automation capabilities, and all supporting business processes. We are also in the process of reducing the number of global data centers that we employ to manage our business.

The following table shows our operating expenses and the associated percentages of revenue.

(In thousands, except percentages)	Three Months Ended May 31,			Percentage Change	Six Months Ended May 31,			Percentage Change
	2011	2010			2011	2010		
Operating expenses:								
Cost of revenue	\$142,979	\$112,938	27	%	\$271,163	\$218,144	24	%
As a percent of revenue	44	% 42	%		44	% 43	%	
SG&A expense	\$105,668	\$89,059	19	%	\$207,440	\$173,711	19	%
As a percent of revenue	33	% 33	%		33	% 34	%	
Depreciation and amortization expense	\$20,714	\$14,269	45	%	\$38,915	\$28,099	38	%
As a percent of revenue	6	% 5	%		6	% 6	%	
Supplemental information:								
	\$87,307	\$72,744	20	%	\$167,835	\$139,526	20	%

SG&A expense excluding  
stock-based compensation

As a percent of revenue	27	%	27	%	27	%	28	%
-------------------------	----	---	----	---	----	---	----	---

Cost of Revenue and Sales Margins

For the three and six months ended May 31, 2011, compared to 2010, cost of revenue increased in line with the increase in revenue. Total sales margins, which we define as revenue less cost of sales, divided by total sales, are modestly lower in the three and six months of 2011, primarily because of lower sales margins in our recent acquisitions. The following table shows

19

---

Table of Contents

the sales margin percentages and percentage point change by operating segment.

(Percentages)	Three Months Ended May 31,		Percentage Change	Six Months Ended May 31,		Percentage Change
	2011	2010		2011	2010	
Americas sales margin	56.8	% 59.0	% (2.2 )%	57.6	% 58.6	% (1.0 )%
EMEA sales margin	54.3	% 55.6	% (1.3 )%	53.7	% 54.8	% (1.1 )%
APAC sales margin	60.2	% 62.5	% (2.3 )%	59.6	% 61.5	% (1.9 )%
Total sales margin	56.0	% 57.6	% (1.6 )%	56.3	% 57.0	% (0.7 )%

In general, sales margins generated by our recent acquisitions caused decreases in each of the segment margins, but were offset to some degree by operational improvements, including organic growth increases and cost control.

## Selling, General and Administrative (SG&amp;A) Expense

We evaluate our SG&A expense excluding stock-based compensation expense. We are investing more heavily in our colleagues, with enhanced 2011 compensation and increased training and development opportunities. Even with this increased focus on our people, we continue to manage the cost structure of our business, and SG&A expense has consequently remained flat as a percentage of revenue compared to the prior-year periods.

## Depreciation and Amortization Expense

For the three and six months ended May 31, 2011, compared to 2010, depreciation and amortization expense increased primarily due to the increase in depreciable and amortizable assets from capital expenditures and acquisitions.

## Acquisition-related Costs

Please refer to Note 6 to the Condensed Consolidated Financial Statements in this quarterly report on Form 10-Q for a discussion of our first and second quarter 2011 costs incurred for integration and other acquisition-related activities. We incurred \$1.2 million of costs in the second quarter of 2011, and have incurred \$4.5 million of costs year-to-date for these activities. Because acquisitions are a key component of our growth strategy, we expect that we will continue to perform similar activities for future acquisitions, and we intend to identify these costs in a separate line item of our financial statements.

## Restructuring

Please refer to Note 7 to the Condensed Consolidated Financial Statements in this quarterly report on Form 10-Q for a discussion of our third quarter 2010 restructuring activities. We incurred \$9.1 million of restructuring charges in the third quarter of 2010. In the second quarter of 2011, we increased our restructuring cost estimate by a net \$0.7 million, which represented increased contract termination costs to exit space in one of our facilities, partially offset by favorable resolution of employee severance costs.

## Operating Income by Segment (geography)

(In thousands, except percentages)	Three Months Ended May 31,		Percentage Change	Six Months Ended May 31,		Percentage Change
	2011	2010		2011	2010	
Americas operating income	\$54,786	\$54,430	1 %	\$104,105	\$101,098	3 %
As a percent of segment revenue	28	% 32	%	28	% 32	%

Edgar Filing: JPMORGAN CHASE & CO - Form 424B2

EMEA operating income	19,614	17,312	13	%	36,111	29,993	20	%
As a percent of segment revenue	21	% 23	%		20	% 21	%	
APAC operating income	9,865	7,875	25	%	18,126	14,176	28	%
As a percent of segment revenue	30	% 34	%		29	% 32	%	
Shared services operating income	(33,295 )	(30,286 )			(67,070 )	(59,198 )		
Total operating income	\$50,970	\$49,331	3	%	\$91,272	\$86,069	6	%
As a percent of total revenue	16	% 19	%		15	% 17	%	

For the three and six months ended May 31, 2011, compared to 2010, the decrease in Americas and EMEA operating

20

---



Table of Contents

income as a percentage of revenue is primary due to recent acquisition activity. Depreciation and amortization associated with the intangible assets of the recent acquisitions has primarily impacted the Americas and EMEA segments, and we have incurred acquisition-related costs as part of the integration efforts for those acquisitions. The increase in APAC operating income is driven primarily by a combination of acquisitions and organic growth.

## Provision for Income Taxes

Our effective tax rate for the three and six months ended May 31, 2011 was 21.2% and 21.1%, respectively, compared to 21.7% and 23.6% for the same respective periods of 2010. The 2011 effective tax rate reflects the full-year benefit from a tax election made during the second quarter of 2010. We currently expect our full year 2011 GAAP tax rate to be in the 21-22% range.

## Adjusted EBITDA (non-GAAP measure)

All of the reconciling items included in the following table are either (i) non-cash items (e.g., depreciation and amortization, stock-based compensation, non-cash pension and post-retirement expense) or (ii) items that we do not consider to be useful in assessing our operating performance (e.g., income taxes, acquisition-related costs, restructuring charges, income or loss from discontinued operations, and gain or loss on sale of assets). In the case of the non-cash items, we believe that investors can better assess our operating performance if the measures are presented without such items because, unlike cash expenses, these adjustments do not affect our ability to generate free cash flow or invest in our business. For example, by eliminating depreciation and amortization from EBITDA, users can compare operating performance without regard to different accounting determinations such as useful life. In the case of the other items, we believe that investors can better assess operating performance if the measures are presented without these items because their financial impact does not reflect ongoing operating performance.

(In thousands, except percentages)	Three Months Ended May 31,		Percentage Change	Six Months Ended May 31,		Percentage Change	
	2011	2010		2011	2010		
Net income	\$38,722	\$38,478	1	% \$69,438	\$65,301	6	%
Interest income	(306)	(94)		(491)	(198)		
Interest expense	2,145	295		3,807	660		
Provision for income taxes	10,401	10,652		18,517	20,180		
Depreciation and amortization	20,714	14,269		38,915	28,099		
EBITDA	\$71,676	\$63,600	13	% \$130,186	\$114,042	14	%
Stock-based compensation expense	19,291	17,640		41,389	36,942		
Restructuring charges (credits)	702	(82)		702	(82)		
Acquisition-related costs	1,243	—		4,549	—		
Non-cash net periodic pension and post-retirement expense	2,604	853		5,207	1,704		
Loss from discontinued operations, net	8	—		1	126		
Adjusted EBITDA	\$95,524	\$82,011	16	% \$182,034	\$152,732	19	%
Adjusted EBITDA as a percentage of revenue	29.4	% 30.8	%	29.4	% 30.1	%	

Our Adjusted EBITDA for 2011 increased primarily because of our improving organic revenue growth, the acquisitions we have made, and the leverage in our business model. Consistent with performance in the past two quarters, acquisitions completed in the last twelve months suppressed margins by about 160 basis points during the

second quarter of 2011, and foreign currency impacts held margins down by another 50 basis points. After considering these impacts, our operational margin expansion was about 70 basis points over the second quarter of 2010. Relative to the margin drag from acquisitions, we expect the aggregate margins of our recent acquisitions to steadily improve over the next four to eight quarters, becoming accretive by the end of 2012.

Financial Condition

21

---

Table of Contents

(In thousands, except percentages)	As of May 31, 2011	As of November 30, 2010	Dollar change	Percent change
Accounts receivable, net	\$244,239	\$ 256,552	\$(12,313 )	(5 )%
Accrued compensation	33,859	51,233	(17,374 )	(34 )%
Deferred subscription revenue	492,051	392,132	99,919	25 %

We have historically experienced seasonal decreases in our accounts receivable balance in the second and third quarters, as we typically have the most subscription renewals in our fiscal first and fourth quarters. This trend continued in 2011. The change in accrued compensation is primarily due to the 2010 bonus payout made in early 2011, partially offset by current year accruals. The increase in deferred subscription revenue was primarily attributable to organic and acquisition-related growth, as well as successfully completing annual renewals on time.

Year-over-year, our deferred revenue balance increased \$120 million, or 32%, and the organic growth rate within deferred subscription revenue was approximately 12% as of May 31, 2011. This organic growth rate metric is a directional, and not a precise, indicator of future revenue performance.

## Liquidity and Capital Resources

As of May 31, 2011, we had cash and cash equivalents of \$147 million, of which approximately \$117 million is currently held by our foreign subsidiaries. We also had \$295 million of debt as of May 31, 2011. We have generated strong cash flows from operations over the last few years. On a trailing twelve-month basis, our conversion of Adjusted EBITDA to free cash flow was 68%. The conversion ratio was held down by an increase in receivables aging, but we expect that ratio to revert to approximately 70% in the coming quarters. Because of our cash, debt, and cash flow positions, as well as the new financing that we secured in January 2011, we believe we will have sufficient cash to meet our working capital and capital expenditure needs.

Our future capital requirements will depend on many factors, including the level of future acquisitions, the need for additional facilities or facility improvements, the timing and extent of spending to support product development efforts, the expansion of sales and marketing activities, the timing of introductions of new products, changing technology, investments in our internal business applications, and the continued market acceptance of our offerings. We could be required, or could elect, to seek additional funding through public or private equity or debt financing for any possible future acquisitions; however, additional funds may not be available on terms acceptable to us or at all. We expect to incur approximately \$50-55 million in capital expenditures in 2011.

## Cash Flows

(In thousands, except percentages)	Six Months Ended May 31,			
	2011	2010	Dollar change	Percent change
Net cash provided by operating activities	\$200,981	\$ 179,156	\$21,825	12 %
Net cash used in investing activities	(243,748 )	(102,159 )	(141,589 )	139 %
Net cash provided by (used in) financing activities	(17,621 )	14,158	(31,779 )	(224 )%

The increase in net cash provided by operating activities was principally due to increased billings and collections in the first six months of 2011. Our subscription-based business model continues to be a cash flow generator that is aided by the following factors:

- positive working capital characteristics that do not generally require substantial working capital increases to support our growth;
- relatively low levels of required capital expenditures; and
- our well-capitalized balance sheet.

The increase in net cash used in investing activities was principally due to significant acquisition activity in the second quarter of 2011, as well as a significant increase in capital expenditures for our various investment initiatives in facilities and infrastructure.

The increase in net cash used in financing activities for the six months of 2011 was principally due to reduced net borrowings, as well as the payment of debt issuance costs.

Free Cash Flow (non-GAAP measure)

22

---

Table of Contents

The following table reconciles our non-GAAP free cash flow measure to net cash provided by operating activities.

(In thousands, except percentages)	Six Months Ended May 31,		Dollar change	Percent change
	2011	2010		
Net cash provided by operating activities	\$200,981	\$179,156		
Capital expenditures on property and equipment	(32,531	) (16,339	)	
Free cash flow	\$168,450	\$162,817	\$5,633	3 %

Our free cash flow has historically been very healthy, and we expect that it will continue to be a significant source of funding for our business strategy of growth through organic and acquisitive means. We expect capital expenditures to stay in the range of 3-4% of revenue for the near term.

#### Credit Facility and Other Debt

Please refer to Note 10 to the Condensed Consolidated Financial Statements in this quarterly report on Form 10-Q for a discussion of the current status of our new term loan and revolving credit agreement.

#### Share Repurchase Program

Please refer to Part II, Item 2 in this quarterly report on Form 10-Q for a discussion of our share repurchase programs.

#### Off-Balance Sheet Transactions

We have no off-balance sheet transactions.

#### Critical Accounting Policies

Our management makes a number of significant estimates, assumptions and judgments in the preparation of our financial statements. See “Management’s Discussion and Analysis and Results of Operations—Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for fiscal year 2010 for a discussion of the estimates and judgments necessary in our accounting for revenue recognition, valuation of long-lived and intangible assets and goodwill, income taxes, pension and post-retirement benefits, and stock-based compensation.

#### Item 3. Quantitative and Qualitative Disclosure About Market Risk

For information regarding our exposure to certain market risks, see Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in our Annual Report on Form 10-K for fiscal year 2010.

Our \$300 million term loan is subject to variable interest rates. In April and June of 2011, we entered into interest rate derivative contracts that swap variable interest rates for fixed on \$100 million of the term loan. A hypothetical 10% adverse movement in interest rates related to the contracts would not have a material impact on our financial position and results of operations.

#### Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures.

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures pursuant to Rules

13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act are effective at a reasonable assurance level to ensure that information required to be disclosed in the reports required to be filed or submitted under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Table of Contents

## (b) Changes in internal control over financial reporting.

There were no changes in our internal control over financial reporting that occurred during the period covered by this Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II. OTHER INFORMATION

## Item 1. Legal Proceedings

From time to time, we are involved in litigation, most of which is incidental to our business. In our opinion, no litigation to which we currently are a party is likely to have a material adverse effect on our results of operations or financial condition.

## Item 1A. Risk Factors

There have been no material changes to the risk factors associated with the business previously disclosed in Part I, Item 1A of our 2010 Annual Report on Form 10-K.

## Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides detail about our share repurchases during the three months ended May 31, 2011.

	Total Number of Shares Purchased (1)	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs (2)
March 1 - March 31, 2011	13	\$88.62	—	1,000,000
April 1 - April 30, 2011	5,388	89.10	—	1,000,000
May 1 - May 31, 2011	3,048	86.89	—	1,000,000
Total share repurchases	8,449	\$88.30	—	

(1) Amounts represent shares of common stock surrendered by employees in an amount equal to the statutory tax liability associated with the vesting of their equity awards. We then pay the statutory tax on behalf of the employee. Our board of directors approved this program in 2006 in an effort to reduce the dilutive effects of employee equity grants.

(2) To more fully offset the dilutive effect of our employee equity programs, in March 2011, our board of directors approved a plan authorizing us to buy back up to one million shares per year in the open market. We may execute on this program at our discretion, balancing dilution offset with other investment opportunities of the business, including acquisitions. This plan does not have an expiration date.

## Item 6. Exhibits

## (a) Index of Exhibits

The following exhibits are filed as part of this report:





Table of Contents

Exhibit Number	Description
31.1*	Certification of the Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act.
31.2*	Certification of the Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act.
32*	Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**	XBRL Instance Document
101.SCH**	XBRL Taxonomy Extension Schema Document
101.CAL**	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**	XBRL Taxonomy Extension Label Linkbase Document
101.PRE**	XBRL Taxonomy Extension Presentation Linkbase Document

---

\* Filed electronically herewith.  
 XBRL (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration statement or Prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

Table of Contents

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on June 27, 2011.

IHS INC.

By: /s/ Heather Matzke-Hamlin  
Name: Heather Matzke-Hamlin  
Title: Senior Vice President and Chief Accounting Officer